Kodiak skyrockets on positive study data for 2 eye drugs

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 28 Sept, 16:11 UTC

The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.

science

Sources

• T2Kodiak skyrockets on positive study data for 2 eye drugsBioPharma Dive / Healthcare Dive / MedTech Dive28 Sept, 16:11